FindTrial
Sign In

ADVERSE DRUG REACTIONS (ADRs) TO LEVETIRACETAM (LEV): A CASE SERIES AND CLINICAL INSIGHTS

ADVERSE DRUG REACTIONS (ADRs) TO LEVETIRACETAM (LEV): A CASE SERIES AND CLINICAL INSIGHTS - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/091646
Enrollment
3
Registered
2025-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system Health Condition 2: -

Interventions

Intervention1: Nil: Nil

Sponsors

KIMS, Bangalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. To report three probable cases of rare and unexpected adverse drug reactions with Levetiracetam (LEV) 2. To do ADR causality assessment of all the three cases. 3. Patients on LEV treatment who have developed adverse drug reactions.

Exclusion criteria

Exclusion criteria: Patients not treated with Levetiracetam.

Design outcomes

Primary

MeasureTime frame
1.To report three probable cases of rare and unexpected adverse drug reactions with Levetiracetam (LEV) 2.To do ADR causality assessment of all the three cases. Timepoint: 1.To report three probable cases of rare and unexpected adverse drug reactions with Levetiracetam (LEV) 2.To do ADR causality assessment of all the three cases within 10 days to 1 month of taking the drug—

Secondary

MeasureTime frame
To check for other Adverse drug reactions due to the drug LevetiracetamTimepoint: 10 days & 1 month—

Countries

India

Contacts

Public ContactDr PRIYANKA S

KIMS, Bangalore

drpriyanka110@gmail.com9844093100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026